Morbidity

Percent prevalence of chronic conditions among users of chronic drugs program, 2016*

Chronic conditions	Prevalence
Cardiovascular diseases, atherosclerosis, coagulation problems and hypertension	47%
Diabetes	15%
Ulcers	10%
High cholesterol level	10%
Other diseases (Rheumatism, uric acid, glaucoma, osteoporosis...)	8%
Diseases of the nervous system	3%
Epilepsy	3%
Thyroid Problems	2%
Asthma	2%

*For previous years check the Statistical Bulletins' page

Newly reported HIV cases, 2020

Newly reported HIV cases,2021

Newly reported HIV cases, 2022

New reported HIV cases,2023

New reported HIV cases,2024

https://www.moph.gov.lb/userfiles/files/Prevention/TB%20Program/NTP-NAP%20Annual%20Report-2024.pdf

Number of Measles cases

	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023
Measles	9	1,760	235	39	44	126	952	1070	-	28	95	351

Source :MoPH 01/09/2024

Number of Tuberculosis cases*

Tuberculosis cases	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Total number of cases	630	689	682	666	657	632	668	760	656	466	510	510	540
Number of Lebanese cases	330	341	337	312	305	271	254	288	277	233	263	249	225
Number of Non-Lebanese cases	300	348	345	354	352	361	414	472	379	233	247	261	315

*MOPH National Tuberculosis Program 01/05/2025

The trend in Tuberculosis cases by Nationality between 2019 and 2024

...

187

All

ATC	Name ↓	B/G	Ingredients	Dosage	Form	Price
N03AB02	α PHENYTOIN SODIUM 5% USP	G	Phenytoin (sodium) - 250mg/5ml	5ml	Injectable solution	276,448 L.L
N02BE01	α PARACETAMOL	G	Paracetamol - 1g/100ml	1g/100ml	Injectable solution	191,978 L.L
A04AA01	α ONDANSETRON USP	G	Ondansetron - 8mg/4ml	8mg/4ml	Injectable solution	447,948 L.L
C01CA03	α NORADRENALINE	G	Norepinephrine tartrate - 8mg/4ml	8mg/4ml	Injectable solution	330,201 L.L
P01AB01	α METRONIDAZOL	G	Metronidazole - 500mg/100ml	500mg/100ml	Injectable solution	162,541 L.L
A03FA01	α METOCLOPRAMIDE INJECTION USP	G	Metoclopramide HCl - 10mg/2ml	10mg/2ml	Injectable solution	84,470 L.L
M01AE01	α IBUPROFEN	G	Ibuprofen - 400mg/100ml	400mg/100ml	Injectable solution	383,955 L.L
A03BB01	α HYOSCINE BUTYLBROMIDE	G	Hyoscine butylbromide - 20mg/ml	20mg/ml	Injectable solution	70,392 L.L
N01BB02	α 2% LIDOCAINE HCL USP	G	Lidocaine HCl - 2%	2%	Injectable solution	255,970 L.L
N01BB02	α 1% LIDOCAINE HCL USP	G	Lidocaine HCl - 1%	1%	Injectable solution	76,791 L.L
J01XX08	ZYVOX IV	B	Linezolide - 600mg/300ml	600mg/300ml	Injectable solution	4,414,523 L.L
J01XX08	ZYVOX	B	Linezolide - 600mg	600mg	Tablet	35,584,461 L.L
L01FA01	ZYTUX	BioTech	Rituximab - 500mg/50ml	500mg/50ml	Injectable concentrate for solution	27,724,196 L.L
L01FA01	ZYTUX	BioTech	Rituximab - 100mg/10ml	100mg/10ml	Injectable concentrate for solution	16,463,240 L.L
L02BX03	ZYTIGA	B	Abiraterone acetate - 500mg	500mg	Tablet, film coated	72,384,396 L.L
N05AH03	ZYRWAN OD	G	Olanzapine - 10mg	10mg	Tablet, orodispersible	2,564,819 L.L
N05AH03	ZYRWAN OD	G	Olanzapine - 5mg	5mg	Tablet, orodispersible	831,391 L.L
R06AE07	ZYRTEC	B	Cetirizine (dihydrochloride) - 5mg/5ml		Solution	278,175 L.L
R06AE07	ZYRTEC	B	Cetirizine (dihydrochloride) - 1%	1%	Drops	170,668 L.L
R06AE07	ZYRTEC	B	Cetirizine (dihydrochloride) - 10mg	10mg	Tablet, film coated	593,978 L.L
N05AH03	ZYPREXA VELOTAB	B	Olanzapine - 10mg	10mg	Tablet, dispersible	5,214,109 L.L
N05AH03	ZYPREXA VELOTAB	B	Olanzapine - 10mg	10mg	Tablet, dispersible	5,214,109 L.L
N05AH03	ZYPREXA VELOTAB	B	Olanzapine - 5mg	5mg	Tablet, dispersible	2,607,054 L.L
N05AH03	ZYPREXA VELOTAB	B	Olanzapine - 5mg	5mg	Tablet, dispersible	2,607,054 L.L
N05AH03	ZYPREXA	B	Olanzapine - 10mg	10mg	Tablet	1,468,820 L.L
N05AH03	ZYPREXA	B	Olanzapine - 10mg	10mg	Tablet	1,468,820 L.L
N05AH03	ZYPREXA	B	Olanzapine - 5mg	5mg	Tablet	1,197,364 L.L
N05AH03	ZYPREXA	B	Olanzapine - 5mg	5mg	Tablet	1,197,364 L.L
C10BA06	ZYMPASS	B	Rosuvastatin (calcium) - 40mg, Ezetimibe - 10mg		Tablet, film coated	2,482,077 L.L
C10BA06	ZYMPASS	B	Rosuvastatin (calcium) - 20mg, Ezetimibe - 10mg		Tablet, film coated	2,482,077 L.L

...

187